Fig. 3: Pre-treatment TMEM14C AJ/CJ ratio may predict the RBC TI of MDS subjects on H3B-8800 treatment. | Leukemia

Fig. 3: Pre-treatment TMEM14C AJ/CJ ratio may predict the RBC TI of MDS subjects on H3B-8800 treatment.

From: Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

Fig. 3

A Box plots representing the relationship between pre-treatment TMEM14C AJ/CJ (NanoString) and RBC TI on study by tumor indication. Diagnosis of AML, MDS, or CMML is shown as per central assessment. B ROC curve analyses and ranking of MDS subjects with available pre-treatment TMEM14C AJ/CJ data. C TMEM14C AJ/CJ expression ratio post H3B-8800 treatment in MDS subjects with high pre-treatment TMEM14C AJ/CJ ratio. RBC TI red blood cell transfusion independence, MDS myelodysplastic syndromes.

Back to article page